Typicality: | 0.605 |
Saliency: | 0.555 |
for prevention | 168 | purpose |
for mitigation | 62 | purpose |
in april | 7 | temporal |
product → be approved by → the fda | 301 |
product → be approved by → fda | 80 |
product → be authorized by → fda | 58 |
product → be → fda-approved | 54 |
negative | neutral | positive |
0.202 | 0.439 | 0.360 |
Raw frequency | 493 |
Normalized frequency | 0.555 |
Modifier score | 0.864 |
Perplexity | 35.572 |